Association of blood concentrations of complement split product iC3b and serum C3 with systemic lupus erythematosus disease activity by Kim, Alfred H J et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
3-1-2019 
Association of blood concentrations of complement split product 
iC3b and serum C3 with systemic lupus erythematosus disease 
activity 
Alfred H J Kim 
Vibeke Strand 
Deepali P Sen 
Qiang Fu 
Nancy L Mathis 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Authors 
Alfred H J Kim, Vibeke Strand, Deepali P Sen, Qiang Fu, Nancy L Mathis, Martin J Schmidt, Robin R 
Bruchas, Nick R Staten, Paul K Olson, Chad M Stiening, and John P Atkinson 
420  
Arthritis & Rheumatology
Vol. 71, No. 3, March 2019, pp 420–430
DOI 10.1002/art.40747 
© 2018 The Authors. Arthritis & Rheumatology published by Wiley Periodicals, Inc. on behalf of  
American College of Rheumatology. This is an open access article under the terms of the Creative Commons  
Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the  
original work is properly cited and is not used for commercial purposes.
Association of Blood Concentrations of Complement 
Split Product iC3b and Serum C3 With Systemic Lupus 
Erythematosus Disease Activity
Alfred H. J. Kim,1  Vibeke Strand,2 Deepali P. Sen,1 Qiang Fu,3 Nancy L. Mathis,1 Martin J. Schmidt,4 Robin 
R. Bruchas,4 Nick R. Staten,4 Paul K. Olson,4 Chad M. Stiening,4 and John P. Atkinson1
Objective. To examine correlations between blood levels of complement split product iC3b and serum compo-
nent C3 with clinically meaningful changes in disease activity in patients with systemic lupus erythematosus (SLE).
Methods. A total of 159 consecutive patients with SLE, diagnosed according to the American College of 
Rheumatology or Systemic Lupus International Collaborating Clinics classification criteria, were enrolled in CAS-
TLE (Complement Activation Signatures in Systemic Lupus Erythematosus), a prospective observational study. 
Patients with 1–7 study visits were included in this longitudinal analysis. In addition, 48 healthy volunteers were 
enrolled to establish a normal reference value for the ratio of blood iC3b to serum C3 concentrations. Serum C3 
and C4 levels were measured by nephelometry, and blood iC3b levels were measured by a lateral flow assay. 
SLE disease activity was monitored with the Responder Index 50 instrument of the SLE Disease Activity Index 
2000.
Results. Relative changes in the iC3b:C3 ratio, levels of anti–double- stranded DNA (anti- dsDNA) antibodies, 
and use of a  supraphysiologic dose of prednisone (>7.5 mg/day) each independently correlated with SLE dis-
ease activity, as determined in multilevel multiple logistic regression analyses. Only the iC3b:C3 ratio was sig-
nificantly associated with clinically meaningful improvements in disease activity among patients with SLE who 
were receiving a supraphysiologic dose of prednisone. The iC3b:C3 ratio outperformed C3 and C4 levels with 
regard to discriminating active SLE from inactive SLE, and major flares from no disease activity. The iC3:C3 ra-
tio, anti- dsDNA antibody levels, erythrocyte sedimentation rate, and use of a supraphysiologic prednisone dose 
were each independently associated with the presence of lupus nephritis, whereas none of these measures was 
associated with SLE rash. The association of the iC3b:C3 ratio with lupus nephritis was independent of other 
observed clinical  manifestations.
Conclusion. The ratio of blood iC3b to serum C3 concentrations correlates with the extent of SLE disease activity 
and with clinically meaningful changes in disease activity in patients with SLE. Furthermore, the iC3b:C3 ratio may 
discriminate between active and inactive SLE, and between major flares and no active disease.
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INTRODUCTION
The complement system plays a central role in systemic 
lupus erythematosus (SLE) (1). Its activation by immune com-
plexes drives type III hypersensitivity reactions, leading to inflam-
matory responses in the target tissue. Failure to remove cellular 
debris, a process that is highly dependent on complement, is also 
an important tenet in the pathophysiology of SLE. Its presence 
in tissue serves as a diagnostic tool, and decreased concentra-
tions of serum complement components C4 and C3 can serve 
as markers of active disease (2,3). Complement also influences 
immune cell function, with numerous abnormalities observed in 
mice deficient in various complement components (4). Comple-
ment split products are generated during activation of the com-
plement cascades, which bind to various cell- bound complement 
receptors and elicit effector responses (5).
The correlation between decreased serum complement com-
ponent levels and extent of SLE disease activity was first observed 
in 1951 in 4 patients with active disease and depressed CH50 val-
ues that normalized following treatment with adrenocorticotropic 
hormone therapy (6). Furthermore, an association between nor-
malization of C3 levels and an improved disease activity index was 
observed in studies of renal biopsy tissue from patients with lupus 
nephritis (7). Complement activation increases during SLE flares, 
and therefore complement proteins are predicted to be consumed 
with concomitant generation of activation- derived products at a 
rate proportional to the degree of disease activity (8). However, 
interpretation of values may be confounded because of the 
unknown impact of increased acute- phase production of C3 and 
C4 (9–11), and because some individuals with low C4 gene copy 
numbers have persistently low serum C4 levels (12). Nevertheless, 
clinicians have relied on decreased serum levels of complement 
components C3 and C4 as a key standard to indicate SLE flares.
Improved detection of complement activation would enhance 
clinicians’ ability to more readily assess disease activity and 
promptly identify and treat disease flares in SLE. To overcome the 
limitations in evaluating soluble complement components, inves-
tigators have queried whether complement split products (11,13–
22) are more sensitive measures of complement activation, and 
whether their concentrations in the blood and serum would show 
a strong correlation with SLE disease activity. Recent advances 
in detecting complement split products have renewed interest in 
their assessment in patients with SLE (23,24).
The utility of cell- bound complement activation products 
(CB- CAPs) has been demonstrated in molecular studies of SLE. 
These include erythrocyte- associated C4d (E- C4d) and C3d (E- 
C3d), which may be used to assist in the diagnosis of SLE (25–27) 
and also to possibly monitor SLE disease activity (28,29). How-
ever, 2 issues limit the clinical utility of CB- CAPs: 1) results are 
not rapidly available, because detection requires flow cytometry, 
and 2) erythrocyte measurements are a reflection of complement 
activation and SLE disease activity over the 120- day lifespan of 
the erythrocyte rather than the immediate clinical situation. Efforts 
to measure C3d on other cell types with shorter lifespans (e.g., 
reticulocytes [R- C4d]) have demonstrated better correlation with 
indices of disease activity, including scores on the Safety of Estro-
gens in Lupus Erythematosus National Assessment version of the 
SLE Disease Activity Index (SLEDAI) (30), while C3dg:C3 ratios 
were found to be correlated with disease activity in juvenile arthritis 
(31), rheumatoid arthritis, and SLE (32).
Recently, serum and plasma levels of C3dg (33) and plasma 
levels of C4d (34) were shown to be useful in distinguishing 
between subjects with SLE and healthy controls. Furthermore, 
plasma C4d levels correlated with disease activity in patients with 
SLE and were predictive of the future recurrence of nephritis (34). 
In summary, complement split products appear to offer promise 
as biomarkers of SLE disease activity.
Compared to CB- CAPs, soluble complement split products 
confer the advantage of shorter half- lives and more rapid turna-
round of the results. One such split product, iC3b, is the break-
down product of C3b (35) (for a detailed outline, see Supplemen-
tary Figure 1, available on the Arthritis & Rheumatology web site 
at http://onlinelibrary.wiley.com/doi/10.1002/art.40747/abstract) 
with a half- life of ~90 minutes (36), compared to 2 minutes for 
C3a (37) and C3b (36), and 50 hours for C3d (38). These proper-
ties offer the potential for employing iC3b to measure complement 
activation at the time of sampling. The extremely short half- lives 
of C3a and C3b may prevent their detection (since the sample 
processing time is shorter), while the longer half- life of C3d may 
not reflect concurrent complement activation. Two prior studies 
utilizing enzyme- linked immunosorbent assay (ELISA) to examine 
iC3b levels in SLE patients (18,39) found that plasma and serum 
iC3b levels were increased in patients with active SLE com-
pared to healthy controls. However, these data may have been 
confounded by in vitro activation of C3 (40), which may lead to 
artefactually elevated iC3b levels (24), thereby limiting past deter-
minations of iC3b to serve as a useful biomarker of complement 
activation.
We hypothesized that using the ratio of blood iC3b to 
serum C3 levels may offer a more accurate assessment of 
complement activation when compared to iC3b or C3 levels 
alone, since it measures complement consumption relative to 
production. Physiologically, once a flare initiates, complement 
activation by immune complexes drives iC3b production and 
an inflammatory milieu. Interleukin- 6 generated from this pro-
cess increases hepatic production of C3 and C4 (9–11). In this 
early stage of the flare, iC3b levels are predicted to increase 
as a result of the heightened disease activity, while C3 levels 
may remain above the lower limit of normal (>LLN) because 
of augmented biosynthesis. As complement activation con-
tinues and consumption exceeds production, C3 levels will 
decrease below the LLN (<LLN), and iC3b levels will remain 
above the upper limit of normal (>ULN). When effective treat-
ment begins, the inflammatory milieu attenuates such that C3 
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synthesis and iC3b production decrease as complement acti-
vation slows. The levels of iC3b return to baseline as the levels 
of C3 normalize. Thus, we hypothesized that the iC3b:C3 ratio 
would initially be characterized by iC3b levels >ULN and C3 
levels <LLN, followed by increases in C3 levels to exceed LLN. 
Effective treatment may also normalize iC3b levels. Impor-
tantly, changes in either iC3b or the iC3b:C3 ratio may specif-
ically identify parallel changes in SLE disease activity, possibly 
taking place at a stage earlier than that of clinically apparent 
changes.
To better understand how complement split products could 
be used as actionable data in SLE, we initiated the CASTLE 
(Complement Activation Signatures in Systemic Lupus Erythema-
tosus) study. This prospective observational study seeks to eval-
uate how soluble and cell- bound complement activation signa-
tures are altered in the presence of various disease activity states, 
clinical manifestations, and subsets of SLE. As part of the pilot 
phase of this study, we investigated the longitudinal association of 
blood iC3b levels, serum C3 levels, and iC3b:C3 ratios with SLE 
disease activity, using a novel assay platform that measures iC3b 
with the accuracy of an ELISA but without the complicating factor 
of artefact generation by in vitro activation (24). Furthermore, we 
examined how iC3b levels could correlate with the presence of 
lupus nephritis and occurrence of rash in patients with SLE.
PATIENTS AND METHODS
Study design and ethics approval. The pilot phase of 
CASTLE was implemented as a prospective observational study 
in patients with SLE. The study was designed to examine the 
relationship between blood iC3b and/or serum C3 levels and the 
extent of SLE disease activity. The study was approved by the 
Washington University School of Medicine Institutional Review 
Board (protocol no. 201401105, initially approved March 18, 2014 
and last approved May 4, 2018, and protocol no. 201410004, 
initially approved October 20, 2014 and last approved July 11, 
2016).
Patient recruitment. A total of 159 consecutive patients 
with SLE, whose diagnosis was validated using the American Col-
lege of Rheumatology (41) and/or Systemic Lupus International 
Collaborating Clinics (42) classification criteria, were recruited from 
the Lupus Clinic at Washington University School of Medicine 
from April 2014 to December 2016. Patients with 1–7 visits were 
included in the analysis. Subjects with concomitant blood- borne 
contagious infectious diseases (i.e., hepatitis A, B, or C or HIV), 
cirrhosis, end- stage renal disease, or pregnancy were excluded, 
because complement physiology is altered and not well under-
stood in these cohorts. In addition, subjects suspected of having 
a concurrent bacterial infection at the visit were excluded. Medi-
cations taken at the time of the visit, including the dose of pred-
nisone, were confirmed by each provider (AHJK and DPS).
To determine the normal reference range for the iC3b:C3 
ratio, 48 healthy adult volunteers without any complement- 
mediated conditions (e.g., infection, autoimmunity, and trauma, 
among others) were enrolled. These subjects were not taking 
immunomodulatory medications at the time of sample collection.
Assessment of SLE disease activity. In each patient, 
disease activity was assessed using the SLEDAI 2000 
(SLEDAI- 2K; scale 0–105) at the initial study visit, and the SLE-
DAI- 2K Responder Index 50 (RI- 50) at every subsequent visit 
(43). The SLEDAI- 2K RI- 50 was chosen because it assesses 
≥50% improvement in disease activity based on the SLEDAI- 2K 
disease activity score from which it is derived (44) and is more 
practical for use in the clinical setting than the British Isles 
Lupus Assessment Group disease activity score. Active SLE 
was defined as SLEDAI- 2K or SLEDAI- 2K RI- 50 scores >4 (45). 
In analyses using serology- free SLEDAI- 2K RI- 50 scores (with-
out values for complement and anti–double- stranded DNA 
[anti- dsDNA] antibody levels), scores >2 were considered to 
reflect active disease. Clinically meaningful improvement was 
defined as a decrease of ≥4 in the SLEDAI- 2K RI- 50 scores 
from the prior visit, and clinically meaningful deterioration (i.e., 
flare) was defined as an increase of ≥4 in SLEDAI- 2K RI- 50 
scores from the prior visit. These definitions were derived from 
the original SLEDAI (46) and have been validated for both the 
SLEDAI- 2K (47) and SLEDAI- 2K RI- 50 (48) instruments.
Major flares were determined using the Fortin definition (49), 
which required at least 1 of the following criteria to be fulfilled: 1) 
new or increased prednisone dose >20 mg/day, 2) necessity for 
new or increased immunosuppression, 3) hospitalization due to 
SLE, or 4) death due to SLE.
Each provider received training in scoring disease activity 
using the SLEDAI- 2K RI- 50 instrument (http://www.sri-50.com) 
and each was blinded with regard to the iC3b and iC3b:C3 
determinations during the entire study.
Laboratory assessments and definition of qualita-
tive variables. Levels of iC3b were determined by a lateral 
flow assay, using 2 antigen- specific antibodies (Kypha, Inc.) 
(24). The blood samples used for determination of iC3b were 
diluted 1:100 in a proprietary buffer within 30 minutes of ve ni-
puncture. The buffer was designed to prevent spontaneous 
complement activation and iC3b breakdown (24). The diluted 
samples were then immediately frozen on dry ice and trans-
ferred to a −80°C freezer and stored until assayed. The levels of 
iC3b remained stable for at least 6 months using this approach 
(data not shown).
C3 and C4 levels were measured by nephelometry, and 
anti- dsDNA antibody levels were determined by ELISA. The 
iC3b:C3 ratios (in μg/mg) were calculated as (iC3b × 100)/
C3. Investigations of C3, C4, and anti- dsDNA antibody lev-
els, the erythrocyte sedimentation rate (ESR), and C- reactive 
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 protein (CRP) levels were performed at the core laboratories of 
Barnes- Jewish Hospital in St. Louis, Missouri. The supraphys-
iologic dose of prednisone was defined as a dose >7.5 mg/
day. Race was self- reported.
Statistical analysis. Statistical analyses were per-
formed using SAS version 9.4 (SAS Institute). Descriptive sta-
tistics were summarized as the mean ± SD for continuous 
variables, and proportion for categorical variables. The normal 
reference range for the iC3b:C3 ratio and iC3b levels was cal-
culated using the robust method (50) based on median val-
ues (due to the non- normal distribution of the data and the 
relatively small sample size of the healthy control group). The 
generalized estimating equation (GEE) method was used to 
produce population average estimates across patients while 
accounting for repeated measures in the same patient (51). 
The logit models with GEE were implemented in Proc GEE in 
the SAS statistical package. Binary logistic regression mod-
els examined associations of SLE disease activity with bio-
chemical markers. Ordinal logistic regression models were 
employed to characterize associations between clinically 
meaningful changes in disease activity and biomarkers, since 
the outcome variable is ordinal.
The 3 categories of clinically meaningful changes in dis-
ease activity (clinically meaningful improvement, unchanged, 
and clinically meaningful deterioration) were treated as a con-
tinuum. The average odds of improvement were defined as 
the odds of clinically meaningful improvement compared to 
unchanged disease activity and clinically meaningful dete-
rioration combined. Similarly, the average odds of flare were 
defined as the odds of clinically meaningful deterioration com-
pared to unchanged disease activity and clinically meaningful 
improvement combined. Odds ratios (ORs) and 95% confi-
dence intervals (95% CIs) were estimated.
To examine the sensitivity and specificity of the iC3b:C3 
ratio and levels of iC3b, C3, C4, and anti- dsDNA antibodies for 
different SLE disease outcomes, receiver operator characteristic 
(ROC) curves with GEE analyses were conducted. The areas 
under the ROC curve (AUCs) with 95% CIs were estimated. The 
Mann- Whitney U statistical test was used for the comparison 
of all biomarkers against iC3b:C3 (52). To evaluate the inde-
pendence of the association of iC3b:C3 with lupus nephritis 
(independent of other clinical manifestations of SLE), ordinary 
linear regression with GEE was performed.
RESULTS
Patient characteristics. Baseline characteristics (defined 
as those at the time of entry into the pilot phase of the CASTLE 
study) of the 159 patients with SLE who provided informed con-
sent to participate are described in Table 1. Of the 159 patients, 
89.3% were female, 57.9% were African American and 42.1% 
were of European descent, and the mean ± SD age was 41.3 ± 
13.6 years. With regard to SLE characteristics, 67.8% of patients 
were anti- dsDNA antibody positive, 37.1% were receiving a sup-
raphysiologic dose of prednisone (defined as >7.5 mg/day), and 
18.2% had at least 1 renal manifestation, either urinary casts, pro-
teinuria, hematuria, or pyuria. Of those patients receiving a sup-
raphysiologic dose of prednisone, the mean ± SD dose was 16.1 
± 14.5 mg/day. Furthermore, in patients at baseline, the mean ± 
SD SLEDAI- 2K disease activity score was 5.14 ± 5.74, mean ± 
SD blood iC3b levels were 4.47 ± 2.83 μg/ml (range 0.7–21.0), 
and the mean ± SD iC3b:C3 ratio was 5.01 ± 6.11 μg/mg (range 
0.66–74.51) (Table 1). The characteristics of the 48 healthy control 
subjects are detailed in Supplementary Table 1 (available on the 
Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.40747/abstract).
Association of iC3b:C3 ratios with active SLE dis-
ease status. We first compared the distribution of iC3b:C3 
ratios between patients with active disease, patients with inac-
tive disease, and healthy controls. Patients with active SLE 
had an elevated iC3b:C3 ratio (mean ± SD 7.03 ± 7.84 μg/
mg) as compared to patients with inactive SLE (4.30 ± 2.03 μg/
mg) and healthy controls (1.69 ± 0.57 μg/mg) (Kruskal- Wallis  
H statistic = 132.5, P < 0.0001 for each comparison) (Figure 1A). 
The median ULN of the iC3b:C3 ratio was 2.79 μg/mg (95% CI 
2.51–3.07). Based on this median ULN, 85.2% of patients (195 
of 229) with active SLE and 76.4% of patients (191 of 250) with 
inactive disease had an iC3b:C3 ratio >ULN. When the iC3b:C3 
ratio was used to classify active disease, only 50.2% of patients 
were classified correctly. The persistence of elevated iC3b:C3 
Table  1. Baseline characteristics of the 159 patients with 
systemic lupus erythematosus enrolled in the CASTLE prospective 
observational study* 
Age, mean ± SD years 41.3 ± 13.6
Female, % 89.3
African American, % 57.9
Receiving a supraphysiologic 
dose of prednisone, %†
37.1
 Prednisone dose, mean ± SD 
mg/day
16.14 ± 14.46
SLEDAI- 2K score, mean ± SD 5.14 ± 5.74




Blood iC3b levels, mean ± SD 
(range) μg/ml
4.47 ± 2.83 (0.7–21.0)
Blood iC3b:C3 ratio, mean ± SD 
(range) μg/mg
5.01 ± 6.11 (0.66–74.51)
* CASTLE = Complement Activation Signatures in Systemic Lupus 
Erythematosus; SLEDAI- 2K = Systemic Lupus Erythematosus Dis-
ease Activity Index 2000; anti- dsDNA = anti–double- stranded DNA. 
† Defined as >7.5 mg/day. 
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ratios during periods of disease inactivity confirms prior obser-
vations of C3 hypercatabolism in the majority of patients with 
SLE (53).
In comparison, a small difference in iC3b levels was 
observed between patients with active SLE (mean ± SD 5.95 ± 
2.99 μg/ml) and patients with inactive SLE (5.22 ± 2.68 μg/ml) 
(Figure 1B). The median ULN of iC3b levels was 3.705 μg/ml 
(95% CI 3.266–4.190). Based on this value, 76.9% of patients 
(176 of 229) with active SLE and 62.0% of patients (155 of 
250) with inactive SLE had an iC3b level >ULN. When iC3b 
levels were used to classify active disease, only 53.2% were 
classified correctly.
Furthermore, C3 levels in patients with active disease were 
lower than in those with inactive disease (mean ± SD 103.3 ± 
35.3 mg/dl versus 121.5 ± 25.2 mg/dl) (Figure 1C). Categorizing 
patients according to C3 levels <LLN (<90 mg/dl) correctly clas-
sified 77.2% of patients with active SLE. Nevertheless, C3 levels 
<LLN were observed in only 37.1% (85 of 229) of patients with 
active disease and in 10.0% (25 of 250) of those with inactive dis-
ease, confirming the low sensitivity of C3 levels <LLN for detecting 
active disease.
Since the iC3b:C3 ratio poorly classified active SLE, we 
hypothesized that relative changes in the iC3b:C3 ratio, rather 
than an absolute cutoff, may more sensitively detect active dis-
ease. We examined the strength of association between relative 
changes in the iC3b:C3 ratio and other variables and the pres-
ence of active SLE compared to the presence of inactive SLE. 
In logistic regression analyses in which we examined correla-
tions of disease activity with each individual variable, we found 
that relative changes in the iC3b:C3 ratio, ESR, and levels of 
C3, C4, and anti- dsDNA antibodies each correlated with active 
disease after the analyses had been controlled for the number 
of clinic visits (i.e., number of clinic visits did not confound for 
other examined variables)  (Figure 2A). When all covariates were 
included in the same multiple regression model, only changes 
in the iC3b:C3 ratio, anti- dsDNA antibody level, and use of a 
supraphysiologic dose of prednisone were independently asso-
ciated with active disease (Figure 2B). Furthermore, the strength 
of the association between relative changes in the iC3b:C3 ratio 
and active disease increased when analyses were controlled for 
anti- dsDNA antibody levels and use of a supraphysiologic dose 
of prednisone (OR 1.13 versus OR 1.29 for every 1- unit increase 
in iC3b:C3).
We found similar results using serology- free SLEDAI- 2K RI- 
50 scores for measuring disease activity. Relative changes in the 
iC3b:C3 ratio, C3 levels, and ESR were each associated with 
active disease (Figure 2C) after analyses were controlled for the 
number of clinic visits. In multivariate analysis, relative changes 
in the iC3b:C3 ratio, iC3b levels, and CRP levels and use of a 
supraphysiologic dose of prednisone were each independently 
associated with active disease (Figure 2D). Surprisingly, change 
in iC3b levels was negatively associated with active disease in 
both analyses (Figures 2B and D), after controlling for iC3b:C3 
ratios, CRP levels, and use of a supraphysiologic prednisone 
dose. The strength of the association between changes in the 
Figure  1. Elevated iC3b:C3 ratios are more commonly observed 
in patients with active systemic lupus erythematosus (SLE). The 
distributions of iC3b:C3 ratios (A), serum iC3b levels (B), and serum C3 
levels (C) were compared between patients with active SLE (n = 229), 
patients with inactive SLE (n = 250), and healthy controls (n = 48). 
Values are the mean ± SD. The broken horizontal line indicates the 
upper limit of normal (ULN). * = P < 0.0001; ** = P < 0.008 by 1- tailed 
analysis of variance with Dunn’s correction.
CORRELATION OF IC3B:C3 RATIOS WITH SLE DISEASE ACTIVITY |      425
iC3b:C3 ratio and active disease increased in the multivariate 
analysis (OR 1.06 in individual univariate analysis versus OR 
1.23 in multivariate analysis for every 1- unit increase in the 
iC3b:C3 ratio). These data demonstrate a relationship between 
the iC3b:C3 ratio and SLE disease activity.
Correlation of iC3b:C3 ratios with clinically mean-
ingful changes in SLE disease activity among patients 
receiving a supraphysiologic dose of prednisone. We 
examined whether iC3b:C3 ratios were associated with clinically 
meaningful changes in disease activity using longitudinal data. 
In all study subjects, no biochemical markers were associated 
with clinically meaningful changes in disease activity (Figure 3A), 
although iC3b:C3 ratios trended toward an association.
Since patients who were receiving a supraphysiologic dose 
of prednisone were more likely to have active disease (Fig-
ures 2B and D), we examined clinically meaningful changes in 
disease activity in this subgroup. In our univariate regression 
analysis, only incremental change in the iC3b:C3 ratio had a sta-
tistically significant association with clinically meaningful changes 
in disease activity among patients receiving a supraphysiologic 
dose of prednisone OR 0.95 for clinically meaningful improve-
ment in disease activity for every 1-unit decrease in the iC3b:C3 
ratio, and OR 1.05 for clinically meaningful deterioration for every 
1-unit increase in the iC3b:C3 ratio (Figure 3B).
Better discrimination of SLE disease activity with 
iC3b:C3 ratios than with low C3 or low C4 levels. We 
 evaluated the ability of the iC3b:C3 ratio to discriminate between 
active and inactive SLE, in comparison to the discriminative  abilities 
of iC3b, C3, and C4 levels, by performing ROC curve analyses. 
The iC3b:C3 ratio performed the best in terms of  discriminating 
active disease (AUC 0.6594, 95% CI 0.6076–0.7112), followed 
by anti- dsDNA antibody levels (AUC 0.6578, 95% CI 0.6066–
0.7091), C3 levels (AUC 0.6444, 95% CI 0.5896–0.6993), iC3b 
levels (AUC 0.5909, 95% CI 0.5384–0.6435), and C4 levels 
(AUC 0.6177, 95% CI 0.5615–0.6738) (Figure 4A). We confirmed 
these results using the serology- free SLEDAI- 2K RI- 50 scores for 
Figure  2. The iC3b:C3 ratio is associated with active systemic 
lupus erythematosus (SLE). A and B, Variables were examined 
for association with active disease as determined using the SLE 
Disease Activity Index 2000 (SLEDAI- 2K) scores, in univariate (A) 
and multivariate (B) logistic regression analyses with generalized 
estimating equations (GEE). C and D, Variables were examined for 
association with the serology- free SLEDAI- 2K Responder Index 
50 scores in univariate (C) and multivariate (D) logistic regression 
analyses with GEE. Whisker plots show the average odds ratios with 
95% confidence intervals (95% CIs). Variables that were significantly 
associated with active SLE are shown in red. ESR = erythrocyte 
sedimentation rate; dsDNA = anti–double- stranded DNA; CRP = 
C- reactive protein; AA = African American.
Figure 3. The iC3b:C3 ratio is associated with clinically meaningful 
change in systemic lupus erythematosus (SLE) disease activity in 
patients with more active disease. Variables were examined in 
univariate logistic regression analyses with generalized estimating 
equations for association with clinically meaningful changes in SLE 
disease activity in all study subjects assessed in longitudinal analyses 
(A), and in only those taking a supraphysiologic dose of prednisone 
(daily dose >7.5 mg/day) (B). Whisker plots show the average odds 
ratios with 95% confidence intervals (95% CIs). The statistically 
significant association of the iC3b:C3 ratio with clinically meaningful 
change is shown in red. ESR = erythrocyte sedimentation rate; 
dsDNA = anti–double- stranded DNA; CRP = C- reactive protein; 
AA = African American.
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measuring change in disease activity. The iC3b:C3 ratios (AUC 
0.5931, 95% CI 0.5406–0.6456), anti- dsDNA antibody lev-
els (AUC 0.5688, 95% CI 0.5178–0.6199), and C3 levels (AUC 
0.5807, 95% CI 0.5275–0.6339) were all statistically significant in 
discriminating active disease from inactive disease, whereas iC3b 
levels (AUC 0.4487, 95% CI 0.3965–0.5010) and C4 levels (AUC 
0.5489, 95% CI 0.4944–0.6033) did not show any significant abil-
ity to discriminate active disease from inactive disease (Figure 4B).
We further explored whether the iC3b:C3 ratio could dis-
criminate between patients presenting with a major SLE flare 
(according to the Fortin definition [49]) and patients with no 
disease activity (SLEDAI- 2K RI- 50 score of 0). The iC3b:C3 
ratio was superior in terms of discriminating a major disease 
flare (AUC 0.6611, 95% CI 0.5761–0.7461) compared to 
iC3b levels (AUC 0.6112, 95% CI 0.5252–0.6971), C3 levels 
(AUC 0.6273, 95% CI 0.5379–0.7166), and C4 levels (AUC 
0.5989, 95% CI 0.5071–0.6907) (Figure 4C), but was inferior 
to the discriminative ability of anti- dsDNA antibody levels (AUC 
0.7395, 95% CI 0.6662–0.8128).
Association of the iC3b:C3 ratio with the presence 
of lupus nephritis but not rash. We noted that 16.5% of 
patients with active SLE had normal iC3b:C3 ratios (Figure 1A). 
We hypothesized that certain disease manifestations may not 
drive sufficient systemic complement activation for detection of 
abnormalities in the blood. Thus, we evaluated 2 common man-
Figure 4. The iC3b:C3 ratio has the capacity to discriminate active 
systemic lupus erythematosus (SLE) from inactive SLE, and major 
flares from no disease activity. Receiver operating characteristic 
(ROC) curves using the iC3b:C3 ratio and blood levels of iC3b, 
C3, C4, and anti–double- stranded DNA (anti- dsDNA) antibodies 
were used to discriminate active SLE from inactive SLE using the 
complete SLE Disease Activity Index 2000 (SLEDAI- 2K) Responder 
Index 50 (RI- 50) score (A), active SLE from inactive SLE using the 
serology- free SLEDAI- 2K RI- 50 score (B), and major flare from no 
disease activity (C). AUC = area under the ROC curve; 95% CI = 
95% confidence interval.
Figure  5. The iC3b:C3 ratio is associated with lupus nephritis, 
but not rash, in patients with systemic lupus erythematosus. A and 
B, Variables were examined for association with lupus nephritis 
using univariate (A) and multivariate (B) logistic regression analyses 
with generalized estimating equations (GEE). C, Multiple linear 
regression analysis with GEE was used to assess changes in the 
urinary protein:creatinine (UPC) ratio for a given unit change in each 
biomarker. D, Univariate logistic regression analysis was used to 
examine the association between each variable and lupus rash. 
Whisker plots show the average odds ratios with 95% confidence 
intervals (95% CIs). Variables that were significantly associated with 
lupus nephritis are shown in red. ESR = erythrocyte sedimentation 
rate; dsDNA = anti–double- stranded DNA; CRP = C- reactive protein; 
AA = African American.
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ifestations of SLE that we speculated would drive different levels 
of complement activation, rash and lupus nephritis (defined as 
having any non- zero score in the urinary cast, hematuria, pro-
teinuria, or pyuria domains of the SLEDAI- 2K RI- 50 score).
We first compared the presence of lupus nephritis in 
SLE patients to a status of no disease activity (patients with a 
SLEDAI- 2K RI- 50 score of 0). In the univariate regression analy-
ses, relative changes in iC3b levels, the iC3b:C3 ratio, C3 levels, 
ESR, and anti- dsDNA antibody levels as well as race and number 
of visits each correlated with the presence of lupus nephritis (Fig-
ure 5A). In the multivariate regression analyses, only changes in 
the iC3b:C3 ratio, anti- dsDNA antibody levels, and ESR and use 
of a supraphysiologic dose of prednisone independently correlated 
with the presence of lupus nephritis (Figure 5B). A 1- unit increase 
in the iC3b:C3 ratio increased the odds of lupus nephritis by 45%.
Since other clinical manifestations of SLE may contribute 
to the iC3b:C3 ratio, we examined whether the association 
of iC3b:C3 ratios with lupus nephritis may be confounded by 
these other manifestations. Using ordinary linear regression 
with GEE, we found that iC3b:C3 ratios were associated with 
the presence of lupus nephritis independent of the presence 
of pleurisy, pericarditis, leukopenia, thrombocytopenia, arthritis, 
rash, alopecia, and mucocutaneous ulcers (see Supplementary 
Table 2, available on the Arthritis & Rheumatology web site at 
http://onlinelibrary.wiley.com/doi/10.1002/art.40747/abstract). 
No such independent association was observed in the pres-
ence of vasculitis or myositis, although these data may be a 
reflection of a lack of statistical power.
We then examined the quantitative changes in urinary pro-
tein:creatinine (UPC) ratios for every unit change in iC3b levels, 
iC3b:C3 ratios, C3 levels, C4 levels, anti- dsDNA antibody levels, 
ESR, and CRP levels. Only relative changes in the iC3b levels had 
a statistically significant association with the UPC ratio (P = 0.006), 
with an increase in the UPC ratio of 0.18 for every 1- μg/ml increase 
in the iC3b level (Figure 5C). Both the iC3b:C3 ratios and C3 levels 
trended toward a significant association (for iC3b:C3, P = 0.097; 
for C3 levels, P = 0.100), with an increase in the UPC ratio of 0.10 
for every 1- unit increase in the iC3b:C3 ratio, and an increase in 
the UPC ratio of 0.01 for every 10- mg/dl decrease in the C3 level.
When we examined the strength of association of iC3b:C3 
ratios with the presence of lupus rash only, in comparison to that 
in patients with no active disease, no correlation was observed 
(Figure 5D). Moreover, none of the other biochemical measures 
(anti- dsDNA antibody levels, C3 levels, C4 levels, ESR, or iC3b 
levels) correlated with the presence of lupus rash. This establishes 
that the iC3b:C3 ratio may not correlate with all disease manifes-
tations in SLE.
DISCUSSION
Clinicians currently assess complement activation on the 
basis of a reduction <LLN in the serum complement compo-
nents C3 and C4. However, several factors limit the usefulness 
of these measures in tracking SLE disease activity. For example, 
during SLE flares, consumption (due to activation) and produc-
tion (due to inflammation- induced liver production as part of the 
acute- phase response) of C3 and C4 occur, which may prevent 
their early detection.
Complement activation generates numerous soluble and 
surface- bound split products that interact with stimulatory com-
plement receptors and membrane- bound regulators of comple-
ment activation. Consequently, the value of measuring comple-
ment split products has just begun to be realized. For example, 
increased erythrocyte- and platelet- bound C4d can provide util-
ity in the diagnosis of SLE (25–28).
A major unmet need in SLE is identifying biomarkers 
that might consistently reflect the levels of disease activity. To 
address this problem, we examined whether iC3b:C3 ratios 
were associated with changes in SLE disease activity. We 
employed a lateral flow assay designed to rapidly determine 
blood iC3b levels in the absence of artefactual elevation of 
iC3b (24). We provide evidence that the iC3b:C3 ratio corre-
lated with changes in SLE disease activity, with clinically mean-
ingful changes in disease activity evident in patients receiving 
a supraphysiologic dose of prednisone, and with the presence 
of lupus nephritis in SLE patients. In addition, the iC3b:C3 
ratio was demonstrated to have favorable characteristics for 
identifying active SLE and major SLE flare. The performance 
characteristics of the iC3b:C3 ratio compare favorably with 
those of C3 or C4 levels in the serum.
Furthermore, we found an association between iC3b:C3 
ratios and the presence of lupus nephritis that was independent 
of other observed clinical manifestations of SLE, and the levels of 
iC3b correlated with the UPC ratio. These results are not surpris-
ing, given the significant degree of complement activation asso-
ciated with lupus nephritis. Our findings support the use of the 
iC3b:C3 ratio as a biomarker of lupus nephritis disease activity.
Our data also confirm the lack of usefulness of absolute 
cutoff values, derived from healthy controls, for interpreting the 
levels of complement components or split products, in relation 
to SLE disease activity. We determined that elevated iC3b lev-
els or iC3b:C3 ratios poorly classified active disease (identify-
ing ~50% of patients). Low C3 levels also had poor sensitivity 
in detecting active disease (identifying 37.1% of patients). The 
poor sensitivity of low C3 levels is likely attributable to patients 
who experienced disease flares and had reductions in C3 lev-
els that remained above the LLN but were lower than their 
baseline C3 levels during disease inactivity. This has previously 
been observed in patients with lupus nephritis (54). In contrast, 
the regression analyses demonstrated a positive correlation 
between the iC3b:C3 ratio and active disease, independent 
of other biomarkers evaluated. These results indicate that a 
relative change in complement levels likely has more value in 
assessing disease activity than an absolute cutoff value.
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The lateral flow assay employed in this study offers rapid 
and precise measurements of iC3b. Results are obtained in 20 
minutes with the accuracy of an ELISA (24). A cassette that 
measures C3 using lateral flow assay has recently been pro-
duced, and data from a prototype possessed an accuracy that 
was similar to that of nephelometry (24). Thus, following addi-
tional validation, dual measurements of iC3b and C3 levels could 
potentially be obtained to generate the iC3b:C3 ratio as a point- 
of- care test.
Lower blood iC3b levels were independently associated 
with higher odds of active disease for a given iC3b:C3 ratio, 
anti- dsDNA antibody level, and use of a supraphysiologic dose 
of prednisone. This finding is surprising, because the production 
of iC3b should increase with complement activation. We initially 
speculated that the expression levels of complement receptors 
in SLE may influence iC3b levels. The surface density of the iC3b 
receptors CR1 and CR2 are inversely correlated with SLE dis-
ease activity (55). CR1 can bind to C3b, inactivate it into iC3b, 
and then into C3dg and C3c (Supplementary Figure 1 [http://
onlinelibrary.wiley.com/doi/10.1002/art.40747/abstract]). Thus, in 
those with more active disease, less iC3b may be formed due to a 
decrease in CR1 expression. Conversely, decreased CR2 expres-
sion in active disease could result in increased iC3b levels due to 
reduced clearance. Furthermore, proteins important in SLE (inter-
feron- α and the downstream product of iC3b proteolysis, C3d) are 
also ligands for CR2 (56), which may further increase iC3b levels 
due to receptor occupancy. Thus, the differences in iC3b receptor 
expression observed during active disease likely do not explain 
why iC3b levels are inversely correlated with disease activity. This 
highlights the need to better characterize the half- lives and sys-
temic and local handling of complement split products, such as 
iC3b, in patients with SLE.
A possible limitation to the use of complement split prod-
ucts for evaluation of SLE disease activity is that not all manifes-
tations may be related to detectable systemic activation of com-
plement. Dermoepidermal junction deposition of C3d and C4d 
are observed in the skin of patients with active SLE rash (57), 
suggesting that complement split products are generated. Nev-
ertheless, we found that lupus rash alone did not correlate with 
changes in the iC3b:C3 ratio. This suggests that a certain thresh-
old of complement activation, perhaps combined with perfusion 
characteristics of the inflamed organ, is required.
We observed that CRP levels were independently associated 
with active disease based on the serology- free SLEDAI- 2K RI- 50 
scores. CRP levels were found to poorly correlate with anti- dsDNA 
antibody levels and low complement levels (58), and thus this 
measure is thought to be poorly associated with disease activity in 
SLE. Nevertheless, increases in the CRP level of ~15 mg/liter have 
been observed during flares, particularly in patients with serositis 
(58). We agree with the findings of others, that increases in the 
CRP level during active disease are attenuated as compared to 
what might be anticipated; this could explain why a signal was 
observed only when anti- dsDNA antibody levels and hypocomple-
mentemia were removed from the analysis.
We acknowledge that there may be variability in how 
iC3b:C3 ratios behave depending on as yet undiscovered 
patient disease characteristics. However, our data demonstrate 
that the measurement of iC3b:C3 ratios is more informative than 
traditional biomarkers. These data support the development 
of larger- scale studies to confirm the utility of iC3b:C3 ratios 
in SLE, especially in identifying those who may develop lupus 
nephritis. Our data also suggest that a comprehensive, quan-
titative assessment of soluble and cell- bound complement split 
products from patients with various disease activity states needs 
to be performed, especially in light of data demonstrating the 
efficacy of complement inhibition in lupus nephritis (59). Iden-
tifying the array of complement signatures in the blood and on 
immune cells longitudinally will likely generate important obser-
vations regarding SLE pathophysiology, and may help refine how 
to best utilize complement split products for the assessment of 
SLE disease activity.
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